Download PDF
Int J Angiol 1992; 1(2): 55-62
DOI: 10.1007/BF02651516
Original Articles

© Georg Thieme Verlag KG Stuttgart · New York

Chagas' cardioneuropathy: Effects of ganglioside treatment on stress-induced arrhythmias. A randomized, double-blind, placebo-controlled study

Daniel Iosa1 , Marco Prosdocimi2 , Mark H. Bradshaw3 , Roberto Fiorentini4
  • 1Centro Privado de Medicina, Cordoba, Argentina
  • 2The Cardiovascular Research Dept., Fidia S.p.A., Abano Terme, Italy
  • 3The Biometrics & Clinical Data Management, Fidia Pharmaceutical Corp, Washington, D.C.
  • 4The Clinical Research & Development, Fidia Pharmaceutical Corp., Washington, D.C., USA
Presented at the 33rd Annual Meeting of the International College of Angiology, Singapore, June 30–July 6, 1991.
Further Information

Publication History

Publication Date:
22 April 2011 (online)

  PDF Download  Permissions and Reprints

Abstract

Chagas' disease is manifested by cardiovascular and autonomic nervous system disorders with arrhythmias and sudden death.

This paper reports the results of an analysis of the mean total arrhythmias (MTA), calculated as the sum of arrhythmias counted after cough, hyperventilation, and postural stress tests, that was conducted as part of a randomized, double-blind, placebo-controlled study. This analysis evaluated the effect on MTA of eight weeks of treatment with Cronassial® (mixed gangliosides) in a 58-patient study, conducted under a U.S. Food and Drug Administration-approved investigational New Drug Application.

Results demonstrated the following: (1) patients receiving placebo during the first four weeks increased in MTA from 0.39 to 1.69, then decreased to 0.69 following four weeks of ganglioside therapy; (2) patients receiving gangliosides in the first four weeks decreased in MTA from 2.70 to 0.41; and (3) the subset of these latter patients who continued with ganglioside therapy for an additional four weeks had a further decrease to 0.36 after a total of eight weeks of ganglioside treatment, while the remaining patients who changed from gangliosides to placebo after week 4 returned to a higher MTA of 1.15. Comparisons between ganglioside- and placebo-treated patients were statistically significant (p<0.05) at both four and eight weeks, favoring ganglioside therapy.

In conclusion, gangliosides reduced the mean number of stress-induced arrhythmias in chronic chagasic patients. This effect may be due to gangliosides' ability to stabilize autonomic control of the heart.